PTGX

121.4002.11%
NY

Newman Yeilding

Executive VP, Chief Scientific Officer

Dr. Newman Yeilding, M.D., is Chief Medical Officer of Santa Ana Bio, Inc. from February 2026. Dr. Yeilding was Chief Scientific Advisor of Protagonist Therapeutics, Inc. from August 1, 2024 to January 1, 2025. Dr. Yeilding had been Executive Vice President and Chief Scientific Officer of Protagonist Therapeutics, Inc. from January 2, 2025 until August 2025 and serves as its Scientific Advisor since August 2025. Dr. Yeilding joins Protagonist following his career at Janssen, where he held a number of senior roles including Head of Immunology Development and R&D, Vice President of Immunology Dermatology, GI Development Senior Director, Vice President Immunology and STELARA and Early Development Compound Development Team Leader. During his time at Janssen, he provided scientific and management leadership of immunology development initiatives in clinical departments including Rheumatology, Gastroenterology, Dermatology and Pediatric Development. He led an R&D organization of approximately 250 members in close collaboration with the Immunology Global Strategic Commercial Organization to accelerate development, commercialization and market access of innovative first-in-class or best-in-class compounds for the global Immunology market. Prior to Janssen, he was the Associate Director of Medical Affairs at Centocor and served as Chief of Hematology-Oncology at the Philadelphia Veterans Administration Medical Center, after spending four years as a research track faculty with research focused on tumor angiogenesis. Dr. Yeilding earned his M.D. from the University of Alabama, Birmingham and a B.S. from Davidson University in North Carolina and completed his residency training in internal medicine at the Hospital of the University of Pennsylvania.

Positions